NLRP6 and steatosis: While another study also claimed that NLRP6 activity negatively regulates NASH progression, the authors showed only enhanced liver damage upon constitutive Nlrp6 deficiency and did not further investigate other parameters of disease progression such as steatosis, inflammation, or fibrosis [32].